Contemporary Tailored Oncology Treatment of Biliary Tract Cancers.
Loading...
Embargo End Date
ICR Authors
Authors
Turkes, F
Carmichael, J
Cunningham, D
Starling, N
Carmichael, J
Cunningham, D
Starling, N
Document Type
Journal Article
Date
2019-12-18
Date Accepted
2019-09-05
Abstract
Biliary tract cancers (BTCs) are poor prognosis malignancies with limited treatment options. Capecitabine has recently emerged as an effective agent in the adjuvant setting; however, treatment of advanced disease is still limited to first-line cisplatin and gemcitabine chemotherapy. Recent global efforts in genomic profiling and molecular subtyping of BTCs have uncovered a wealth of genomic aberrations which may carry prognostic significance and/or predict response to treatment, and several targeted agents have shown promising results in clinical trials. As such, the uptake of comprehensive genomic profiling for patients with BTCs and the expansion of basket trials to include these patients are growing. This review describes the currently approved systemic therapies for BTCs and provides insight into the emerging targeted and immunotherapeutic agents, as well as conventional chemotherapeutic regimes, currently being investigated in clinical trials.
Citation
Gastroenterology Research and Practice, 2019, 2019 pp. 7698786 -
Source Title
Gastroenterology Research and Practice
Publisher
WILEY
ISSN
1687-6121
eISSN
1687-630X
1687-630X
1687-630X
Collections
Research Team
PrCa Targeted Therapy
Medicine (RMH)
Medicine (RMH)